Biogen Inc. has announced the initiation of the global Phase 3 PROMINENT study to evaluate the efficacy and safety of its investigational anti-CD38 monoclonal antibody, felzartamab, compared to ...
PROMIS NEUROSCIENCES ($PMN) posted quarterly earnings results on Monday, March 31st. The company reported earnings of -$0.02 per share, beating estimates of -$0.14 by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results